The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The 2016 World Health Organization classification of tumours of the central nervous system
Abstract
The 2016 WHO classification of tumours of the central nervous system represents the new paradigm among the specialists in the brain tumours and proposes a new approach combining histopathological and molecular features into diagnosis named 'integrated diagnosis'. The aim of this challenge is to overstep the interobserver variability of diagnosis based on previous classifications in order to ensure homogenous biological entities with a more accurate clinical significance. Over the last two decades, several molecular aberrations into gliomagenesis were highlighted and then confirmed as emerging biomarkers through prognostic stratification. In particular, IDH1/IDH2 genes mutations, 1p/19q codeletion and mutations in genes encoding histone H3 variants drastically changed the knowledge about diffuse gliomas inducing the WHO working group to consider the phenotype-genotype approach. In the present review, the historical development of the diagnosis of brain tumours from the 3D spatial configuration to the integration of multidisciplinary data up to recent molecular alterations is discussed. At the national level, the RENOCLIP network (supported by the National Cancer Institute) contributes to improve the standardization of histological diagnosis and the facilitation of access to molecular biology platforms for the detection of genetic aberrations necessary for integrated diagnosis. Importantly, the French POLA cohort allowed to test the clinical impact of the new criteria introduced by 2016 WHO classification of CNS tumours confirming the high accuracy in predicting clinical behaviour for diffuse gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,220
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Histological Typing of Tumours of the Central Nervous System
Kleihues, P., Burger, P. C., & Scheithauer, B. W. (1993) · Springer eBooks · doi:10.1007/978-3-642-84988-6 · Cited by 1,532
Ostrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Grading of astrocytomas: A simple and reproducible method
Daumas-Duport, C., Scheithauer, B., O'Fallon, J., & Kelly, P. (1988) · Cancer · doi:10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t · Cited by 891
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma
Lian, C. G., Xu, Y., Ceol, C., Wu, F., Larson, A., Dresser, K., Xu, W., Tan, L., Hu, Y., Zhan, Q., et al. (2012) · Cell · doi:10.1016/j.cell.2012.07.033 · Cited by 789
Pathology and Genetics of Tumours of the Nervous System
Brada, M. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1562 · Cited by 787
Jenkins, R. B., Blair, H., Ballman, K. V., Giannini, C., Arusell, R. M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1796 · Cited by 763
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Castel, D., Philippe, C., Calmon, R., Le Dret, L., Truffaux, N., Boddaert, N., Pagès, M., Taylor, K. R., Saulnier, P., Lacroix, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1478-0 · Cited by 664
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Louis, D. N., Perry, A., Burger, P., Ellison, D. W., Reifenberger, G., von Deimling, A., Aldape, K., Brat, D., Collins, V. P., Eberhart, C., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12171 · Cited by 580
Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428
KELLY, P. J., DAUMAS-DUPORT, C., SCHEITHAUER, B. W., KALL, B. A., & KISPERT, D. B. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)65470-6 · Cited by 403
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S. M., & Barnholtz-Sloan, J. S. (2015) · Cancer Treatment and Research · doi:10.1007/978-3-319-12048-5_1 · Cited by 400
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M. N., Hedlund, E. K., Rusch, M. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4630 · Cited by 379
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
Wiestler, B., Capper, D., Holland-Letz, T., Korshunov, A., von Deimling, A., Pfister, S. M., Platten, M., Weller, M., & Wick, W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1156-z · Cited by 346
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 283
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Pleomorphic Xanthoastrocytoma: Natural History and Long‐Term Follow‐Up
Ida, C. M., Rodriguez, F. J., Burger, P. C., Caron, A. A., Jenkins, S. M., Spears, G. M., Aranguren, D. L., Lachance, D. H., & Giannini, C. (2015) · Brain Pathology · doi:10.1111/bpa.12217 · Cited by 246
Pérez-Larraya, J. G., Ducray, F., Chinot, O., Catry-Thomas, I., Taillandier, L., Guillamo, J.-S., Campello, C., Monjour, A., Cartalat-Carel, S., Barrie, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8086 · Cited by 212
Wang, P., Wu, J., Ma, S., Zhang, L., Yao, J., Hoadley, K. A., Wilkerson, M. D., Perou, C. M., Guan, K.-L., Ye, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.029 · Cited by 206
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
Labussière, M., Di Stefano, A. L., Gleize, V, Boisselier, B., Giry, M., Mangesius, S., Bruno, A., Paterra, R., Marie, Y., Rahimian, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.538 · Cited by 202
Self-citationAnaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
Ducray, F., Idbaih, A., de Reyniès, A., Bièche, I., Thillet, J., Mokhtari, K., Lair, S., Marie, Y., Paris, S., Vidaud, M., et al. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-41 · Cited by 173
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics
van den Bent, M. J., Weller, M., Wen, P. Y., Kros, J. M., Aldape, K. D., & Chang, S. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now277 · Cited by 170
Two types of chromosome 1p losses with opposite significance in gliomas
Idbaih, A., Marie, Y., Pierron, G., Brennetot, C., Hoang-Xuan, K., Kujas, M., Mokhtari, K., Sanson, M., Lejeune, J., Aurias, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20607 · Cited by 167
Molecular diagnostics of gliomas: the clinical perspective
Tabatabai, G., Stupp, R., van den Bent, M. J., Hegi, M. E., Tonn, J. C., Wick, W., & Weller, M. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0750-6 · Cited by 155
Yang, P., Cai, J., Yan, W., Zhang, W., Wang, Y., Chen, B., Li, G., Li, S., Wu, C., Yao, K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now021 · Cited by 127
Feng, J., Hao, S., Pan, C., Wang, Y., Wu, Z., Zhang, J., Yan, H., Zhang, L., & Wan, H. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.07.002 · Cited by 123
Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort
For POLA Network, Tabouret, É., Nguyễn, A. T., Dehais, C., Carpentier, C., Ducray, F., Idbaïh, A., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1611-8 · Cited by 109
Vogazianou, A. P., Chan, R., Bäcklund, L. M., Pearson, D. M., Liu, L., Langford, C. F., Gregory, S. G., Collins, V. P., & Ichimura, K. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop075 · Cited by 84
α-Internexin expression identifies 1p19q codeleted gliomas
Ducray, F., Crinière, E., Idbaïh, A., Mokhtari, K., Marie, Y., Paris, S., Navarro, S., Laigle–Donadey, F., Dehais, C., Thillet, J., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000339055.64476.cb · Cited by 58
Groenen, P. J. T. A., Blokx, W. A. M., Diepenbroek, C. J. M., Burgers, L., Visinoni, F., Wesseling, P., & van Krieken, J. H. (2011) · Histopathology · doi:10.1111/j.1365-2559.2010.03711.x · Cited by 54
Mokhtari, K., Ducray, F., Kros, J. M., Gorlia, T., Idbaïh, A., TAPHOORN, M. J. B., Wesseling, P., Hoang‐Xuan, K., van den Bent, M. J., & Sanson, M. (2011) · Cancer · doi:10.1002/cncr.25827 · Cited by 37
Zanello, M., Pallud, J., Baup, N., Peeters, S., Turak, B., Krebs, M., Oppenheim, C., Raphaël Gaillard, B., & Devaux, B. C. (2017) · Neurosurgical FOCUS · doi:10.3171/2017.6.focus17250 · Cited by 26
Garinet, S., Néou, M., Villéon, B. D. L., Faillot, S., Sakat, J., da Fonseca, J. P., Jouinot, A., Tourneau, C. L., Kamal, M. T., Rondof, W., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.06.005 · Cited by 15
Cited by
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Subtypes of medulloblastoma have distinct developmental origins
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., et al. (2010) · Nature · doi:10.1038/nature09587 · Cited by 831
Orringer, D. A., Pandian, B., Niknafs, Y. S., Hollon, T. C., Boyle, J., Lewis, S., Garrard, M., Hervey-Jumper, S. L., Garton, H. J. L., Maher, C. O., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0027 · Cited by 568
Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022) · Cancer · doi:10.1002/cncr.33918 · Cited by 372
Overview of quantitative susceptibility mapping
Deistung, A., Schweser, F., & Reichenbach, J. R. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3569 · Cited by 338
Metadata
- Authors
- Villa, C., Miquel, C., Mosses, D., Bernier, M., & Di Stefano, A. L.
- Venue
- La Presse Médicale
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 47
- Issue
- 11-12
- Pages
- e187-e200
- ISSN
- 0032-7867 (ISSN-L)
- 0755-4982
- OpenAlex
- W2901166159
- Cited by
- 319
- References
- 57
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.